Andrew Harline

Cooley advised KPay Group, a one-stop financial management and business operations platform, on the completion of its first institutional funding round at $55 million.

Cooley advised Zepto, India’s fast-growing quick commerce company, on its $340 million Series G financing at a $5 billion valuation.

Cooley advised Zepto, India’s fast-growing quick commerce company, on its $665 million Series F financing, more than doubling its valuation to $3.6 billion in less than a year.

San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.